T
Tilman B. Drüeke
Researcher at French Institute of Health and Medical Research
Publications - 415
Citations - 22817
Tilman B. Drüeke is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Kidney disease & Hyperparathyroidism. The author has an hindex of 68, co-authored 413 publications receiving 21471 citations. Previous affiliations of Tilman B. Drüeke include Versailles Saint-Quentin-en-Yvelines University & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Control of vascular smooth-muscle cell growth by macrophage-colony-stimulating factor.
Thierry Herembert,Jean Gogusev,Dingliang Zhu,Tilman B. Drüeke,Tilman B. Drüeke,Pierre Marche +5 more
TL;DR: The hypothesis that M-CSF affects the growth of cultured rat VSMCs through paracrine/autocrine mechanisms is supported and its effects at both the macrophage and the VSMC level confer to M- CSF a central role in the development of vascular lesions that occurs during atherosclerotic progression.
Journal ArticleDOI
An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO study.
Angel L.M. de Francisco,Joseph Kim,Stefan D. Anker,Vasily Belozeroff,Bernard Canaud,Charles Chazot,Tilman B. Drüeke,K.-U. Eckardt,Jürgen Floege,Florian Kronenberg,Iain C. Macdougall,Daniele Marcelli,Bart Molemans,Jutta Passlick-Deetjen,Guntram Schernthaner,Peter Stenvinkel,David C. Wheeler,Bruno Fouqueray,Pedro Aljama +18 more
TL;DR: ARI revealed differences in HD practice patterns and patient characteristics in the 10 participating countries and will fill gaps in the knowledge about the care of European HD patients.
Journal ArticleDOI
Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease.
Pablo Ureña-Torres,Marc G. Vervloet,Sandro Mazzaferro,Franck Oury,Vincent Brandenburg,Jordi Bover,Etienne Cavalier,Martine Cohen-Solal,Adrian Covic,Tilman B. Drüeke,Elif Hindié,Pieter Evenepoel,João M. Frazão,David Goldsmith,Junichiro James Kazama,Mario Cozzolino,Ziad A. Massy +16 more
TL;DR: The skeletal action of PTH in early CKD stages to the steadily increasing activation of the often downregulated PTH receptor type 1 has been critically reviewed, emphasizing that therapeutic strategies to decrease PTH levels at these stages might not be recommended.
Introduction and definition of CKD-MBD and the development of the guideline statements
Sharon M. Moe,Tilman B. Drüeke,Geoffrey A. Block,Jorge B. Cannata-Andía,GJ Elder,M Fukagawa,Jorgetti,Markus Ketteler,Craig B. Langman,Adeera Levin,Alison M. MacLeod,Linda M. McCann,PA McCullough,SM Ott,Aym Wang,Weisinger,David C. Wheeler,K.-U. Eckardt,Bertram L. Kasiske,K Uhlig,R Moorthi,Amy Earley,R Persson +22 more
TL;DR: The principal conclusion was that the term ‘CKD–Mineral and Bone Disorder (CKd–MBD)’ should be used to describe the broader clinical syndrome encompassing mineral, bone, and calcific cardiovascular abnormalities that develop as a complication of CKD (Table 1).